https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29481 n = 144, 71%), followed by mouth spray (n = 84, 42%) and vaporiser (n = 83, 41%). Explanations for preferences (n = 134) most commonly cited convenience (n = 66; 49%). A total of 82% (n = 168) of respondents indicated that they had no trial-related concerns, but a small number volunteered concerns about adverse effects (n= 14) or wanted more information/advice (n = 8). Six respondents volunteered a belief that cannabis might cure cancer, while two wanted assurance of efficacy before participating in a trial. Conclusion: Justification of modes other than tablets/capsules and variable understanding about cannabis and trials will need addressing in trial-related information to optimise recruitment and ensure that consent is properly informed.]]> Wed 17 Nov 2021 16:32:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7304 Sat 24 Mar 2018 10:44:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5011 Sat 24 Mar 2018 07:44:12 AEDT ]]>